Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer
Abstract
Purpose
To investigate the efficacy of curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer.
Materials and methods
Twenty-two colorectal cancer patients who received three-dimensional conformal radiotherapy (n
=
20) or helical tomotherapy (n
=
2) for isolated retroperitoneal lymph node recurrence were analyzed retrospectively. Radiation dose was 55.8
Gy in 31 fractions or 63
Gy in 35 fractions, and 60
Gy in 20 fractions by helical tomotherapy. All patients received concurrent chemotherapy and 16 (72.7%) received adjuvant chemotherapy.
Results
The treatment response was complete in 13 (59.1%), partial in 6 (27.3%), and stable in 3 (13.6%) patients. Median follow-up for 11 (50%) surviving patients was 32
months (range, 27–61). The 3- and 5-year overall survival rates were 64.7% and 36.4%, and median overall survival was 41
months. Recurrences developed in 15 (68.2%) patients; outside the retroperitoneum in 13. The 3- and 5-year recurrence-free survival rates were 34.1% and 25.6%, and median recurrence-free survival was 20
months. Response and adjuvant chemotherapy were significant prognostic factors for overall survival. Gastrointestinal toxicity
⩾
Grade 3 was not observed.
Conclusions
Definitive chemoradiotherapy is an effective salvage treatment for isolated retroperitoneal lymph node recurrence of colorectal cancer without severe complications.
Keywords: Isolated, Retroperitoneal lymph node, Recurrence, Oligometastasis, Colorectal cancer, Chemoradiotherapy
To access this article, please choose from the options below
PII: S0167-8140(10)00396-8
doi:10.1016/j.radonc.2010.05.021
© 2010 Elsevier Ireland Ltd. All rights reserved.
